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Precision public health is a new field driven by technological advances that enable more 
precise descriptions and analyses of individuals and population groups, with a view to 
improving the overall health of populations. This promises to lead to more precise clinical 
and public health practices, across the continuum of prevention, screening, diagnosis, 
and treatment. A phenotype is the set of observable characteristics of an individual 
resulting from the interaction of a genotype with the environment. Precision (deep) phe-
notyping applies innovative technologies to exhaustively and more precisely examine the 
discrete components of a phenotype and goes beyond the information usually included 
in medical charts. This form of phenotyping is a critical component of more precise diag-
nostic capability and 3-dimensional facial analysis (3DFA) is a key technological enabler 
in this domain. In this paper, we examine the potential of 3DFA as a public health tool, 
by viewing it against the 10 essential public health services of the “public health wheel,” 
developed by the US Centers for Disease Control. This provides an illustrative framework 
to gage current and emergent applications of genomic technologies for implementing 
precision public health.
Keywords: public health, 3D facial scan, rare diseases, spatial information, genomics and genetics, developmental 
disabilities
iNtrODUctiON
Rare diseases (RD) are increasingly recognized nationally (1) and globally as a public health priority 
(2, 3). While individually, RD have a low prevalence, it is estimated that the combined prevalence is 
between 6 and 8% of the population (2, 4). Most RD have a genetic association and are often severely 
debilitating, impair physical and mental abilities, and shorten life expectancy (5). These characteristics 
present clinical and public health challenges. These include the need for early and accurate diagnosis 
FigUre 1 | some functionality of 3DFA. The purple line around the facial 
periphery demonstrates a cropping and facial segmentation tool. White dots are 
automated land marking. The vertical purple line demonstrates an application of 
the measuring tool, in this case showing a 17.1 mm philtral length.
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and for identifying emerging technologies to enhance the delivery 
of clinical and public health practices for affected individuals (1).
The RD community has collectively nominated timely 
accurate diagnosis and earlier intervention with improved 
therapeutic options as key issues (6). This context and this chal-
lenge also provide opportunities for innovation and creating 
new knowledge. One such opportunity for improved diagnosis 
and treatment is through the clarity that can be achieved 
with detailed analysis and representation of the phenotype of 
genetic and rare disorders. Broadly, a phenotype is the set of 
observable characteristics of an individual resulting from the 
interaction of a genotype with the environment; in medicine, 
it is used to describe some deviation from normal morphology, 
physiology, or behavior. Greater phenotypic clarity is being 
advanced through imaging, the use of standards for phenotypic 
description, and their combination. This “precision” or “deep” 
phenotyping affords medicine and science a unique opportunity 
to generate biological insights.
An emerging deep phenotyping application is 3-dimensional 
facial analysis (3DFA). In the RD domain, 3DFA has been 
investigated and is increasingly being implemented, primarily 
for diagnostic purposes (7–9). 3DFA is also being applied to 
monitor existing and novel therapies, an area in which it has a 
nascent role (10, 11). 3DFA involves the investigation of deeply 
precise 3D facial data that can be acquired with various facial 
imaging technologies and applied to deliver scientific insights. 
The technological innovations enabling 3DFA include advances 
in imaging hardware, analytical techniques, and the combination 
with other, e.g., text-based, advances.
Approaches such as 3DFA, and other forms of deep phenotyp-
ing, mean that RD are providing a fruitful domain for precision 
approaches to medicine and public health. This is highlighted 
by a series of targeted precision initiatives in multiple countries, 
including in the United States, programs based at the National 
Institutes of Health at the Centers for Mendelian Genetics and the 
Undiagnosed Diseases Program and Network (12, 13); in Japan, 
via its Agency for Medical Research and Development under its 
rare and intractable diseases pillar; and in Western Australia (WA), 
through a coordinated suite of initiatives being implemented 
under the WA Rare Diseases Strategic Framework 2015–2018 (1, 9).
PrecisiON tecHNOLOgies  
iN PUBLic HeALtH
Precision public health has been defined as “the application 
and combination of new and existing technologies, which more 
precisely describe and analyze individuals and their environment 
over the life course, in order to tailor preventive interventions for 
at-risk groups and improve the overall health of the population.” 
Thus, precision public health complements and extends precision 
medicine’s focus by recognizing that precise interventions are 
needed at both the individual and population levels.
Herein, we outline the state of play of current and emergent 
3DFA applications, specifically within a precision public health 
paradigm, and using congenital and rare disorders as an exem-
plar. As an illustrative framework, we use the 10 essential public 
health services of “the public health wheel” (14). This framework 
operationalizes the three core functions of public health, namely, 
assessment, policy-making, and assurance.
MONitOr HeALtH stAtUs tO iDeNtiFY 
AND sOLve cOMMUNitY HeALtH 
PrOBLeMs
Congenital anomalies are an important class of mainly RD 
accounting for 12–15% of people with RD and are also known as 
birth defects (15). The causes of these conditions can be divided 
into genetic (e.g., monogenic disorders), multifactorial (e.g., cleft 
palate), and environmental exposures [e.g., fetal alcohol syndrome 
(FAS)]. Congenital anomalies accounted for 732,000 disability-
adjusted life years lost, in 2010, in Western Europe alone (16).
A considerable proportion of congenital anomalies are 
associated with facial dysmorphology (17), either through the 
presence of congenital anomalies in known syndromes with well-
documented facial dysmorphology (e.g., cardiac anomalies in 
Noonan syndrome), or in the recurrent co-coding of individual 
congenital anomalies and facial dysmorphism in individuals (17). 
Furthermore, hundreds of disorders (18), which are collectively 
and variably described as “dysmorphic syndromes” or “develop-
mental disorders,” have characteristic facies. In these instances, 
3DFA has potential to contribute to the improved speed and 
accuracy of diagnosis for a sizeable proportion of the general 
population. This will contribute to more accurate epidemiological 
data, including more precise estimates of the incidence, preva-
lence, and burden of congenital disorders.
DiAgNOse AND iNvestigAte HeALtH 
PrOBLeMs AND HeALtH HAZArDs iN 
tHe cOMMUNitY
3-Dimensional facial analysis is being developed for deeply 
precise diagnostic applications across a broad range of typically 
rare conditions with well-established facial dysmorphic patterns 
(8), see Figures  1 and 2. Additionally, it is increasingly and 
objectively unlocking hitherto undetected, or underappreciated, 
FigUre 2 | the tool has modular analysis components. This figure 
demonstrates one such module, curvature analysis, which is demonstrated in 
a yellow-blue color scale.
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facial diagnostic signatures (7). For example, speech delay is 
common in rare conditions, and in one study of kindergarten 
children, approximately 7% had language-specific impairments 
(19). A potential 3DFA application is using facial signatures as 
early predictors of language delay, either in those from the gen-
eral population or in those at high familial risk, e.g., siblings of 
children with autism. The presence of a group of rare disorders, 
characterized by severe speech impairment and with overlapping 
facial features, collectively called Angelman-like syndromes 
(20), supports the possibility of using facial signatures to predict 
speech delay. There are also numerous other rare disorders that 
are associated with variable degrees of speech delay, e.g., Cornelia 
de Lange syndrome and biologically related disorders (21), that 
have characteristic, and overlapping facial phenotypes. It is likely 
that other children, with or without known syndromes, will have 
facial signatures that are indicative of speech delay that may offer 
a novel way for early screening for language delay to target early 
intervention.
iNFOrM, eDUcAte, AND eMPOWer 
PeOPLe ABOUt HeALtH issUes
We all have a face. It is our unique expression of who we are, 
it reflects our life experiences and communicates our emotions 
to the world. From birth, our faces are a window to our being 
and our portal of interaction with our world. Our faces speak of 
the community from whence we came, and of the communities 
to which we belong, the ultimate expression of our connection 
as individuals. Our face is a canvas for the arts, a window for 
education, a living record of the diversity of the environment and 
our origins. Our face is also a biological billboard that advertises 
our physical and mental wellness, our aging, and our disease. We 
commonly say, “you look ill,” “you look well,” “you look in pain,” 
and we can, for instance, readily recognize a child with Down’s 
syndrome by their facial features. Objectively documenting and 
harnessing these facial clues that underlie common parlance and 
innate recognition capacities, can be used to inform, educate, and 
empower people for health.
A person who has a 3D image taken of their face can almost 
immediately see the computer-generated image. This recogniz-
able and relatable image enables patients and their families 
to gain a new perspective of their health, or the health of a 
relative. Within WA, the technology has recently been used 
with primary school students who participated in a project 
to support equitable innovation for Aboriginal health. As the 
parameters of normal facial contours vary with ethnicity, it is 
important to compile reference scans for different ethnic groups. 
The children involved in this project were delighted to be able 
to view and manipulate their 3D facial images. “They especially 
loved being able to turn their faces upside down to look up 
their noses!” (22).
MOBiLiZe cOMMUNitY PArtNersHiPs 
AND ActiON tO iDeNtiFY AND sOLve 
HeALtH PrOBLeMs
Projects focusing on the delivery of novel ways to diagnose 
and monitor rare disorders have been undertaken with the key 
support of patient advocacy organizations in Australia (e.g., 
Rare Voices Australia, Fabry Australia, Mucopolysachharide 
and Related Diseases Society Australia, Short Statured People’s 
Association of Australia) and internationally (e.g., International 
MPS Network, Costello Syndrome Family Association, CFC 
International). Similarly, projects focused on equitable health 
innovation to address RD have been developed and delivered 
in partnership with Aboriginal leaders, health workers, and 
communities. These projects have been important to the devel-
opment of interest in and application of 3DFA.
The desire to address RD, together with the multifarious and 
crosscutting aspects of faces described above, has provided a 
unique vehicle for mobilizing community partnerships to engage 
in the identification and solution of health problems. A 2015 
event organized as part of an ongoing platform for harmoniz-
ing translational research across premier hospitals, research 
institutes, government, and the community is an illustrative case 
(23). The “Faces of WA” event coalesced cross-sector interest in 
3DFA applications from across science, arts, research, education, 
and data analytics communities.
DeveLOP POLicies AND PLANs tHAt 
sUPPOrt iNDiviDUAL AND cOMMUNitY 
HeALtH eFFOrts
In 2015, WA released the state-wide WA Rare Diseases Strategic 
Framework 2015–2018 (1), which includes, but is not limited, 
to the following objectives: build on existing services for RD 
diagnosis and screening; identify emerging technologies to 
4Baynam et al. Facing Precision Public Health
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enhance the delivery of health care for RD, including to rural 
and remote areas; engage with people living with RD, their car-
ers and families; promote active participation of people living 
with RD with their health care; build epidemiology and health 
system evidence for RD by improving diagnosis and disease 
classification; and strengthen clinical and translational research 
in RD. The implementation of 3DFA contributes to most of these 
objectives.
An example of a disease-specific policy in WA is the Fetal 
Alcohol Spectrum Disorders (FASD) Model of Care (24). FASD has 
been prioritized as a public health issue in Australia and other 
countries, and a cohesive, multilevel, and community-focused 
suite of approaches is required to address this preventable 
disorder group. The FASD Model of Care identifies health care 
and public health prevention strategies as the most important 
means of reducing FASD. The implementation and use of 3DFA 
has the potential to address several of these recommendations, 
including but not limited to screening and early diagnosis. FAS 
is part of the of FASD continuum for which characteristic facial 
features are obligate for diagnosis. These facial characteristics are 
known to vary by ethnicity (25, 26), and there is a paucity of 
data on the Australian Aboriginal population. A pragmatic, but 
potentially imprecise, approach using African-American facial 
standards has been implemented for FAS diagnosis. Should these 
be unfit for purpose, epidemiological, and diagnostic data may be 
inaccurate with implications for targeted health and prevention 
strategies. Potentially, the ethnic variation of Aboriginal facial 
features could be more objectively addressed with the precision 
of currently available 3D approaches.
eNFOrce LAWs AND regULAtiONs 
tHAt PrOtect HeALtH AND eNsUre 
sAFetY
Clinicians and public health practitioners advocate for, review, 
evaluate, revise, educate, and enforce compliance with laws and 
regulations. This must include new and existing laws and regula-
tions related to the use of genomic and other technologies, and 
the information generated from their use (27).
The genetic and genomic information about individuals, 
and that obtained from 3DFA, forms part of and expands 
the individual’s health information. It may also provide 
information about the individual’s relatives, which may be 
of interest to them, especially where prevention or treatment 
is available. Health professionals may inform the individual 
of how the genetic information relates to their relatives; 
however, confidentiality requirements prevent the disclosure 
of this information to the relatives, without the consent of 
the individual, except in specific circumstances outlined in 
relevant legislation and regulations. Internationally and vari-
ably, legislation has been enacted to regulate the collection, 
use, and disclosure of health information. In Australia, the 
2006 amendments to the Privacy Act 1988 allow for health 
practitioners to use or disclose an individual’s genetic informa-
tion, without their consent, where there is a reasonable belief 
that doing so is necessary to lessen or prevent a serious threat 
to the life, health, or safety of their relatives. Irrespective of 
jurisdictional differences in legislation and its implementation, 
the principle remains that new phenotypic technologies that 
reveal indications of familial disease may have implications for 
life insurance, employment, and reproductive choices, so they 
need to conform with legislated codes for privacy protection, 
disclosure, and data sharing.
LiNK PeOPLe tO NeeDeD PersONAL 
HeALtH services AND AssUre tHe 
PrOvisiON OF HeALtH cAre WHeN 
OtHerWise UNAvAiLABLe
Linking people to needed services includes developing mecha-
nisms to assure the provision of such services to marginalized and 
underserved populations. In relation to RD, three such population 
groups in WA are people living with long-standing undiagnosed 
conditions, those living in rural and remote areas, and Aboriginal 
Australians. Improved diagnostic services utilizing new genomic 
technologies and 3DFA are enabling more equitable access to 
services for these populations.
At the level of state-wide clinical practice, 3DFA has been 
implemented in services that improve population access to RD 
diagnostics. The Rare and Undiagnosed Diseases Diagnostic 
service at Genetic Services of WA (9) integrates genomic diag-
nostics into a state-wide clinical service that includes outreach 
clinics. The Undiagnosed Diseases Program Western Australia is 
a cross-disciplinary service provided within the local children’s 
hospital but also accessible to children across the state. These 
complementary programs aim to find diagnoses for those with 
long-standing, undiagnosed conditions.
Given the (increasing) transportability and reducing cost of 
3D facial imaging systems, 3DFA is being implemented in remote 
outreach clinics by initially using a model of periodic deployment 
of a portable camera. Permanent placement of scanners in key 
regional locations is planned for the future. This is to facilitate 
point-of-care diagnostics, treatment, and monitoring and to 
enhance referral, i.e., by pairing submission of 3D images with 
text-based referrals and consultation processes.
AssUre cOMPeteNt PUBLic AND 
PersONAL HeALtH-cAre WOrKFOrce
Facial gestalt is key to diagnosis for numerous genetic conditions 
(e.g., Velocardiofacial syndrome, Williams syndrome, Noonan 
syndrome) and non-genetic conditions [e.g., fetal valproate 
syndrome (FAS)]. Through the creation of tools that objectively 
determine facial patterns and unlock knowledge, diagnostic 
ability and workforce competency can be improved. The increas-
ingly transportable nature of the approach also suits capacity 
building in remote regions; training in 3DFA could contribute to 
workforce development. Coupled with the non-invasive nature 
of 3DFA, this increasing portability, and the very nature of faces, 
it also provides a unique opportunity to engage with this new 
technology as a bridge to deeper engagement with other (e.g., 
genomic) technologies.
5Baynam et al. Facing Precision Public Health
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evALUAte eFFectiveNess, 
AccessiBiLitY, AND QUALitY OF 
PersONAL AND POPULAtiON-BAseD 
HeALtH services
The value of clarifying a diagnosis is undeniable (28). Improved 
diagnostic certainty through the precision of 3DFA provides novel 
opportunities to evaluate health care, for instance, in assessing the 
diagnostic programs for rare genetic diseases through direct and 
objective comparison of facial phenotypic and molecular diag-
nostic approaches. Additionally, by improving certainty of the 
diagnosis of RD, one could more accurately assess interventions 
targeted to the reduction of the burden of these conditions. Given 
the marked disparity between the proportion of the population 
with RD and their combined health system costs, supporting the 
need for early diagnosis and intervention has the potential to 
drive cost savings across the health system (29).
3-Dimensional facial analysis is being used to monitor the 
effectiveness of drug therapy, which provides new avenues to 
assess drug response for both localized facial anomaly (10) and 
systemic disease (11). An example of 3DFA’s use to monitor 
drug response was an application in mucopolysaccharidosis 
type I (MPS I). This lysosomal storage disease is caused by the 
body’s inability to produce a specific enzyme, it expresses a 
pattern of progressive facial dysmorphology and it is treatable 
by drug therapy. 3DFA was used to monitor a child with MPS 
I undergoing treatment to demonstrate that the rate at which 
facial dysmorphology was advancing was reduced (11). 3DFA 
has also been used to monitor a child receiving a treatment 
(rapamycin) for a craniofacial anomaly. This child had extensive 
facial malformations and monitoring of their facial features using 
3DFA showed a progressive improvement in their condition (10). 
In addition to observing treatment and disease progression in a 
standard clinical setting, 3DFA may also have a monitoring role 
in clinical trials.
reseArcH FOr NeW iNsigHts AND 
iNNOvAtive sOLUtiONs tO HeALtH 
PrOBLeMs
Rare diseases are a hot bed for technological innovation and 
recurrently discoveries in RD have delivered innovations for 
common diseases (30). While 3DFA is yielding translational 
insights into innovations for diagnosis, treatment, and monitor-
ing in the RD domain, it is also particularly suited to examining 
the overlap between rare and more common diseases. Notably, 
population level studies demonstrated that common genetic vari-
ations (polymorphisms) were associated with discrete patterns of 
facial variation. Notably, these facial signatures recapitulated the 
characteristic facies of the respective genetic syndrome due to rare 
genetic variation (pathogenic mutations). This highlights further 
evidence of the overlap between common and rare phenotypes 
with implications for possible reciprocal (rare-common) insights.
An example of a common disease that is poised for 3D facial 
translational research is obstructive sleep apnea (OSA). Through 
determining the facial signatures of OSA, 3DFA can be used as a 
complementary tool for OSA screening and classification. Again 
reflecting the potential for joint insights into rare and common 
diseases, OSA is a condition seen in RD, where it regularly has an 
earlier onset than in the general population (e.g., MPS syndromes).
A further promising area is face-to-text conversion. Conver-
sion of a 3D facial image to standardized text-based descriptive 
terms known as human phenotype ontology (HPO) is an ideal 
way to achieve this. These standardized terms can be used com-
putationally (i.e., are machine readable) and can then be used for 
report generation and for integration with text-based diagnostics. 
Face-to-text conversion has been performed for a limited subset 
of facial HPO terms (31). It needs to be extended to the full set 
and be further validated by human experts.
cONcLUsiON
3-Dimensional facial analysis is a prototypical precision public 
health tool that delivers non-invasive, non-irradiating, transport-
able, and community engaging deep phenotyping. It enables mul-
tisector applications that can be increasingly implemented across 
the spectrum of public health. It can be applied to individuals as 
well as for single RD. Finally, insights generated in RD could be 
investigated in more common diseases.
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